SHIJIAZHUANG, China, March 21, 2022 /PRNewswire/ -- On March 19, the Media Briefing on Prevention and control of COVID-19 with Lianhua Qingwen pills, a patented chinese drugs developed and produced by using Yiling Pharmaceutical, changed into convened in Shijiazhuang metropolis, Hebei Province, at which the in vitro experimental outcomes of Lianhua Qingwen tablets in opposition t SARS-CoV-2 Omicron variant with the aid of Guangzhou Institute of Respiratory fitness these days have been published. These experimental outcomes demonstrate that Lianhua Qingwen pills have large inhibiting impact on the cytopathic impact precipitated with the aid of Omicron variant as a way to achieve the anti-novel coronavirus effect.
Lianhua Qingwen capsules (PRNewsfoto/Yiling Pharma)
seeing that the outbreak of the COVID-19, a collection of simple and scientific researches on Lianhua Qingwen tablets towards SARS-CoV-2 had been conducted, forming a sequence of proof for medicine of COVID-19 with Lianhua Qingwen with legit effect on "mobilephone-animal-scientific". primary analysis effects display that Lianhua Qingwen have strong in vitro antivirus impact on COVID-19, whether wild-classification or subsequent assorted mutants, can tremendously improve the cytopathic impact led to by means of virus infection, and may inhibit the free up of proinflammatory components. At latest, in vitro experimental results of Omicron variant have been posted, which has first rate impact. The animal experiment on Lianhua Qingwen capsules in opposition t Omicron is engaging in; the international multicenter medical research has been performed in a number of international locations.
The research outcomes of "Efficacy and protection of Lianhuaqingwen drugs for the Prevention of Coronavirus disorder 2019: A prospective Open-Label controlled Trial" posted on the facts-primarily based Complementary and choice medication demonstrate that Lianhua Qingwen pills can enormously cut back the infection cost of close contacts and the incidence fee of indicators for sufferers who are fantastic in nucleic acid examine, certainly the incidence rate of fever, in order to deliver new therapeutic regimens for suspected instances and shut contacts of COVID-19.
within the analysis and treatment Protocol for COVID-19 (Trial edition 9) published by means of chinese language govt on March 14, Lianhua Qingwen drugs are counseled for prevention and handle of the population under clinical statement and mild and typical patients throughout clinical medication. Lianhua Qingwen tablets have been recommended for remedy of COVID-19 for six times within the national protocol considering the fact that the outbreak of COVID-19.
supply Yiling Pharma
0 Comments